Logo image of TGAN

TRANSPHORM INC (TGAN) Stock Fundamental Analysis

NASDAQ:TGAN - Nasdaq - US89386L1008 - Common Stock - Currency: USD

5.1  +0.34 (+7.14%)

After market: 5.0998 0 (0%)

Fundamental Rating

2

Taking everything into account, TGAN scores 2 out of 10 in our fundamental rating. TGAN was compared to 110 industry peers in the Semiconductors & Semiconductor Equipment industry. While TGAN seems to be doing ok healthwise, there are quite some concerns on its profitability. TGAN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TGAN has reported negative net income.
In the past year TGAN has reported a negative cash flow from operations.
In the past 5 years TGAN always reported negative net income.
In the past 5 years TGAN always reported negative operating cash flow.
TGAN Yearly Net Income VS EBIT VS OCF VS FCFTGAN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

TGAN has a Return On Assets of -127.67%. This is amonst the worse of the industry: TGAN underperforms 94.44% of its industry peers.
TGAN has a worse Return On Equity (-228.50%) than 86.11% of its industry peers.
Industry RankSector Rank
ROA -127.67%
ROE -228.5%
ROIC N/A
ROA(3y)-56.82%
ROA(5y)-113.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TGAN Yearly ROA, ROE, ROICTGAN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -10K -20K -30K

1.3 Margins

TGAN has a worse Gross Margin (18.77%) than 78.70% of its industry peers.
The Profit Margin and Operating Margin are not available for TGAN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TGAN Yearly Profit, Operating, Gross MarginsTGAN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

TGAN does not have a ROIC to compare to the WACC, probably because it is not profitable.
TGAN has more shares outstanding than it did 1 year ago.
TGAN has a worse debt/assets ratio than last year.
TGAN Yearly Shares OutstandingTGAN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
TGAN Yearly Total Debt VS Total AssetsTGAN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

TGAN has an Altman-Z score of 0.88. This is a bad value and indicates that TGAN is not financially healthy and even has some risk of bankruptcy.
TGAN has a worse Altman-Z score (0.88) than 72.22% of its industry peers.
There is no outstanding debt for TGAN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.88
ROIC/WACCN/A
WACC12.3%
TGAN Yearly LT Debt VS Equity VS FCFTGAN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

TGAN has a Current Ratio of 1.69. This is a normal value and indicates that TGAN is financially healthy and should not expect problems in meeting its short term obligations.
TGAN has a Current ratio of 1.69. This is in the lower half of the industry: TGAN underperforms 77.78% of its industry peers.
TGAN has a Quick Ratio of 1.69. This is a bad value and indicates that TGAN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.88, TGAN is doing worse than 86.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.69
Quick Ratio 0.88
TGAN Yearly Current Assets VS Current LiabilitesTGAN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

TGAN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.32%.
Looking at the last year, TGAN shows a small growth in Revenue. The Revenue has grown by 2.74% in the last year.
The Revenue has been growing by 11.44% on average over the past years. This is quite good.
EPS 1Y (TTM)-7.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
Revenue 1Y (TTM)2.74%
Revenue growth 3Y11.44%
Revenue growth 5YN/A
Sales Q2Q%4.01%

3.2 Future

The Earnings Per Share is expected to grow by 8.24% on average over the next years. This is quite good.
The Revenue is expected to grow by 45.75% on average over the next years. This is a very strong growth
EPS Next Y24.61%
EPS Next 2Y18.84%
EPS Next 3Y8.24%
EPS Next 5YN/A
Revenue Next Year37.91%
Revenue Next 2Y49.23%
Revenue Next 3Y45.75%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TGAN Yearly Revenue VS EstimatesTGAN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
TGAN Yearly EPS VS EstimatesTGAN Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -0.1 -0.2 -0.3 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TGAN. In the last year negative earnings were reported.
Also next year TGAN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TGAN Price Earnings VS Forward Price EarningsTGAN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TGAN Per share dataTGAN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.84%
EPS Next 3Y8.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TGAN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRANSPHORM INC

NASDAQ:TGAN (6/20/2024, 8:00:00 PM)

After market: 5.0998 0 (0%)

5.1

+0.34 (+7.14%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)06-25 2024-06-25/amc
Earnings (Next)08-12 2024-08-12/amc
Inst Owners2.78%
Inst Owner Change0%
Ins Owners0.19%
Ins Owner Change0%
Market Cap323.14M
Analysts77.78
Price Target5.66 (10.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.74%
Min EPS beat(2)-19.83%
Max EPS beat(2)-17.65%
EPS beat(4)1
Avg EPS beat(4)-6.44%
Min EPS beat(4)-19.83%
Max EPS beat(4)30.28%
EPS beat(8)2
Avg EPS beat(8)-9.45%
EPS beat(12)5
Avg EPS beat(12)17.27%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.54%
Min Revenue beat(2)-25.76%
Max Revenue beat(2)-7.33%
Revenue beat(4)0
Avg Revenue beat(4)-17.17%
Min Revenue beat(4)-32.96%
Max Revenue beat(4)-2.66%
Revenue beat(8)2
Avg Revenue beat(8)-9.25%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)6.25%
EPS NQ rev (3m)6.25%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)8.08%
Revenue NQ rev (3m)8.08%
Revenue NY rev (1m)2.63%
Revenue NY rev (3m)2.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.23
P/FCF N/A
P/OCF N/A
P/B 17.71
P/tB 18.86
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.3
BVpS0.29
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -127.67%
ROE -228.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.77%
FCFM N/A
ROA(3y)-56.82%
ROA(5y)-113.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 166.21%
Cap/Sales 10.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.69
Quick Ratio 0.88
Altman-Z 0.88
F-Score4
WACC12.3%
ROIC/WACCN/A
Cap/Depr(3y)264.68%
Cap/Depr(5y)166.9%
Cap/Sales(3y)15.02%
Cap/Sales(5y)14.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
EPS Next Y24.61%
EPS Next 2Y18.84%
EPS Next 3Y8.24%
EPS Next 5YN/A
Revenue 1Y (TTM)2.74%
Revenue growth 3Y11.44%
Revenue growth 5YN/A
Sales Q2Q%4.01%
Revenue Next Year37.91%
Revenue Next 2Y49.23%
Revenue Next 3Y45.75%
Revenue Next 5YN/A
EBIT growth 1Y-22.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-64.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.3%
OCF growth 3YN/A
OCF growth 5YN/A